168 results about "Menopausal Symptom" patented technology

A novel herbal extract, MF101, is effective in the treatment of symptoms of menopause.

Methods and devices are described for electrically stimulating nerves and organs to induce and modulate the production of hormones according to desired hormone production patterns and hormone level patterns to treat gynecological conditions. Such methods and devices may be used to treat or alleviate the symptoms of menopause. In addition, such methods and devices may be used for birth control.

A treatment for obesity and overweight comprises administering a vitamin D analog. The analog effectively inhibits an increase in body fat to animals at risk and decreases the basal fat content of animals. The treatment has a positive effect on the lean body component such that while there is an overall decrease in body weight, there is also a decrease in percent body fat. This decrease can be proportionally greater than the overall decrease in body weight. In addition, the treatment has a positive effect on bone turnover and osteogenesis making the vitamin D analog a beneficial treatment for the symptoms of menopause. Various exemplary embodiments of the treatment use the 2-alkylidene derivatives of vitamin D₃, such as the 2-alkylidene-19-nor derivatives in both the R and S configurations at carbon-20.

The disclosure provides compositions comprising liquiritigenin, or derivatives, or prodrugs, useful as estrogen receptor beta selective agonists. The disclosure also provides methods of treating menopausal symptoms, and estrogen-dependent disorders, with said compositions.

The disclosure provides compositions comprising liquiritigenin, or derivatives, or prodrugs, useful as estrogen receptor beta selective agonists. The disclosure also provides methods of treating menopausal symptoms, and estrogen-dependent disorders, with said compositions.

The present invention relates to a use of bamboo or bamboo extract to prevent or treat symptoms related to decrease of androgen; a composition for androgen agonist comprising bamboo or bamboo extract; a method for preventing or treating symptoms related to decrease of androgen by administering composition for androgen agonist; and a method of preparing composition for androgen agonist. The present composition obtained from natural material can be used as Phyto-androgen for the preventing and treating symptoms of male climacteric without dangerousness according to hormone replacement therapy.

The invention pertains to a composition and a method for the treatment of mood disorders, in particular of treating, preventing or alleviating depression, mood disorders or insufficient mood, obesity, overweight, premenstrual syndrome, craving, carbohydrate craving, chocolate craving, menopausal complaints, erectile dysfunction and/or reduced libido, The composition contains cocoa or one or more of its pharmacologically active components, and a dopamine D2 receptor agonist.

The present invention relates to novel 11-beta estradiol ester compounds and their use as locally active estrogens in the treatment of the symptomology of menopause and to treat estrogen sensitive cancers, including breast cancer.

The invention provides a traditional Chinese medicine composition, containing the following raw materials: deer product, semen cuscutae, poria extract, polygala tenuifolia, epimedium, fructus psoraleae, Chinese angelica, white paeony root, eucommia bark, Chinese yam, drynaria baronii, cortex acanthopanacis, medlar, prepared rhizome rehmannia, milkvetch root, black-bone chicken, scutellaria baicalensis, rehmannia root, desert cistanche, malt, medicated leaven, bighead atractylodes rhizome, multiflower knotweed root, caltrop, motherwort, liquorice, donkey-hide gelatine, tortoise-plastron glue, swimming bladder and radix achyranthis bidentatae. The traditional Chinese medicine composition can effectively improve female organism immunocompetence, improve menopausal symptoms and realize beautifying effect. The invention also provides a pill or paste containing the traditional Chinese medicine composition.

The invention relates to ginseng milk and a preparation method, belonging to the technical field of health-care drinks. The ginseng milk is the mixture produced by processing ginseng serous fluid, liquid milk, high-quality white sugar, natural sweetener and emulsion stabilizer; and the preparation method is as follows: fresh or preserved ginseng-ginseng serous fluid-material mixing-milky mixed liquid-homogenization-vacuum degassing-removing of upper-layer oxidation liquid and suspended bubbles-ginseng milk initial liquid-ultra-high temperature sterilization-filling and sealing-finished product. The use of the ginseng milk has the effects of preserving health, conditioning insufficiency of qi, blood and body fluid, enhancing immunity, improving female menopausal symptoms, improving male sexual disorders, prolonging life and promising longevity.

This invention relates to a novel soy isoflavone product with high purities and strong biological activities and the method of producing the same from natural soybeans, soybean materials (i.e. tofu dregs, soy molasses) and other plant sources. The method includes three steps consisting of extraction with an organic solvent, hydrolysis using an acid and crystallization using an antisolvent. The procedure is very simple and thus can be easily adapted for large-scale manufacturing. Moreover, the procedure is able to produce a high yield of total isoflavones at a lower cost. HPLC analysis and E-Screen bioassay reveal that the obtained product not only contains a high content of isoflavone aglycones by weight of dry matter but also exhibits strong estrogenic activity toward human cells. Therefore, the product should be efficacious for relieving menopausal symptoms and other estrogen-deficient diseases and can be used in health care supplements or as additives for foods, beverages or cosmetics.

Androst-5-ene-3β,17β diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, and for conditions which respond well to DHEA treatment, but where a higher ratio of estrogenic to androgenic effects is desired. Combination therapies are included, as are kits and pharmaceutical compositions for providing the active ingredients of claimed methods and combinations.

Embodiments in accordance with the present disclosure are directed to systems and methods for managing hot flashes and/or menopause symptoms. An example system includes sensor circuitry and logic circuitry. The sensor circuitry obtains a physical measurement associated with a user and communicates the physical measurement. The logic circuitry generates a predictive model that indicates a probability of the user having a hot flash at a date and time based on a plurality of input parameters, revises the probability based on the physical measurement using the predictive model, and communicates data indicative of an action in response to the revised probability being outside a threshold, such as providing cooling relief.

Provided herein are a device and method for attenuating posttraumatic stress syndrome, menopause symptoms, dysautonomia and pain by interfering with sympathetic chain signaling, particularly by blocking stellate ganglion conduction.

The invention is to methods for screening women for breast cancer and precancer by determining a level of an estrogen-related marker. The invention further provides methods of treating such patients identified as having one or more abnormal ductal epithelial cells and an estrogen-related marker. The invention provides methods for screening patient for hormone replacement therapy (HRT), and of monitoring such patients once they begin HRT. The invention provides methods of treating peri-, menopausal or postmenopausal women for both cancer risk reduction and menopausal symptoms (or other conditions related to lowered systemic estrogen levels). The invention also provides kits for the screening, monitoring, and treating methods described.

The polypeptides in the present invention possess the effects of promoting and inhibiting the secretion of prolactin, and are thus useful as drugs for the prevention and treatment of various diseases, in terms of prolactin secretion stimulants, which are associated with the secretion of prolactin, such as hypoovarianism, spermatic underdevelopment, menopausal symptoms, hypothyroidism, etc. The polypeptides are useful as drugs for the prevention and treatment of various diseases, in terms of prolactin secretion inhibitors, which are associated with the secretion of prolactin, such as pituitary tumor, diencephalon tumor, menstrual disorder, autoimmune diseases, prolactinoma, sterility, impotence, amenorrhea, lactorrhea, acromegaly, Chiari-Frommel syndrome, Argonz-del Castilo syndrome, Forbes-Albright syndrome, lymphoma, Sheehan's syndrome, spermatogenesis disorder, etc.

The invention provides a soybean isoflavone and phosphatide compound and its preparing process, wherein the molar ratio of soybean isoflavone and phosphatide is 0.5-2 : 1. The preparing process consists of charging organic solvent with low dielectric constant into the mixture, stirring and mixing, filtering the solvent, finally subjecting the filter liquor to decompression drying or freeze drying.

Compounds of structural formula I as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporesis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, arthritis and joint repair, alone or in combination with other active agents.

The invention relates to a female health beverage prepared from tea flower and maca powder, and the female health beverage is characterized by comprising the following raw materials by weight: 45-50 parts of fresh tea flower, 15-17 parts of maca powder, 3-5 parts of lemon, 2-4 parts of raw ginger, 12-15 parts of skim milk powder, 20-25 parts of glucose, 10-15 parts of white granulated sugar and 250 parts of water; the female health beverage is unique in flavor and rich in nutrients, has good health care effect, is suitable for women to drink, has excellent effects of detoxifying, resisting aging, enhancing immunity, regulating human hormone secretion, relieving menopausal symptoms, improving sub healthy state, and improving gynecological inflammation.

Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with pre menopause, menopause, and/or post menopause are described herein. These select phytoestrogen formulations are composed only of two or more plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in the brain. These ERβ-selective phytoestrogen formulations cross the blood-brain-barrier and promote estrogen-associated neurotrophism and neuroprotection mechanisms in the brain, without activating proliferative mechanisms in the reproductive tissues and are therefore devoid of other estrogen-associated problematic aspects. The formulations can be administered enterally, transdermally, transmucosally, intranasally or parenterally. The formulations preferably contain combinations of compounds, and can be formulated for daily, sustained, delayed or weekly/monthly administration. In a preferred embodiment, these are administered to women who are in menopause or post menopausal, most preferably early in menopausal.